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Abstract
Background Patients with critical limb ischemia (CLI) are at increased risk of cardiovascular complications and mortality. 
To determine (1) incidence of myocardial injury following endovascular revascularization, and (2) relationship between 
myocardial injury with 1-year mortality and major adverse cardiovascular events (MACE; i.e., composite of myocardial 
infarction, stroke, and death).
Methods and results Single-center, prospective cohort study of CLI patients ≥ 45 years of age, who underwent endovas-
cular revascularization with overnight hospitalization. High-sensitive troponins T (hsTnTs) were measured on admission, 
3–6 h after endovascular revascularization and the subsequent morning. Myocardial injury after endovascular revasculari-
zation was defined as an hsTnT ≥ 14 ng/L with a relative increase ≥ 30% from the baseline value. We also evaluated other 
myocardial injury hsTnT thresholds (i.e., ≥ 30, ≥ 40, ≥ 60, and ≥ 80 ng/L). 239 consecutive patients (56% male, mean 
age 71.5 ± 10.1 years) were included; one patient was lost to follow-up. At 1 year, there were 34 deaths (14.2%), and 48 
MACE (20.5%). Myocardial injury with the hsTnT threshold of 14 ng/L and relative increase by ≥ 30% from the baseline 
level occurred in 61 patients (25.5%). Myocardial injury was independently associated with 1-year mortality ([aHR], 2.44; 
95% CI 1.18–5.06, for hsTnT ≥ 14 ng/L to aHR, 3.34; 95% CI 1.29–8.65 for hsTnT ≥ 80 ng/L). Myocardial injury was also 
independently associated with 1-year MACE ([AOR] 2.89; 95% CI 1.41–5.92 for hsTnT ≥ 14 ng/L to AOR, 6.69; 95% CI 
2.17–20.68 for hsTnT ≥ 80 ng/L). 85.2% patients who had myocardial injury did not have ischemic clinical symptoms or 
electrocardiography changes. In sensitive analysis with exclusion of symptomatic patients that developed myocardial injury 
for the hsTnT ≥ 14 ng/L threshold, both the 1-year mortality (aHR: 2.19; CI 1.02–4.68; p = 0.04), and 1-year MACE (OR 
2.25; CI 1.06–4.77; p = 0.036) remained significant.
Conclusions Myocardial injury is common following endovascular revascularization for CLI and associated with the risk 
of 1-year mortality and MACE.
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Introduction
Globally > 200 million individuals have lower extremity 
peripheral artery disease (PAD) [1–3]. The predominant 
etiology is atherosclerotic lesions that occlude the arte-
rial lumen, compromising blood flow and resulting in 
ischemia. PAD shares several similarities in pathology 
and predisposing risk factors with coronary artery disease 
(CAD) and ischemic stroke [3, 4]. In all PAD patients, the 
risk of major adverse cardiovascular events (MACE) is 
three to sixfold higher than in the general population [5].
The most advanced stage of PAD is critical limb 
ischemia (CLI). This is a life-threatening condition [6], 
which affects approximately 1–2% of patients with PAD 
[2, 4]. The reported incidence of CLI ranges from 500 to 
1000 per million annually in the general population, and 
has increased by over 20% in the past decade [6].
The standard treatment for CLI is revascularization, 
which should be attempted in the majority of patients 
without delay [6–8]. The aim of this treatment is to obtain 
straight line, unimpeded arterial flow to the foot in at least 
one vessel. This can be performed either with an open 
surgical or percutaneous endovascular approach [9]. Even 
with adequate treatment, CLI carries a substantial burden 
of disability, suboptimal quality of life, and substantial 
health care and social costs [6, 10]. Much of this is due 
to cardiovascular complications [11]. In the first year fol-
lowing the initial diagnosis of CLI mortality reaches 25% 
and surpasses 40% after 2 years [12–14]. In these cases, 
myocardial infarction is responsible for 40–60% of deaths 
and cerebral stroke for another 10–20% [5, 12].
One of possible explanations for this high risk of 
MACE is that revascularization procedures (both surgi-
cal and endovascular) may result in myocardial injury at 
the time of intervention that may impact future prognosis. 
This hypothesis is based on the data from the noncardiac 
surgical setting, where perioperative cardiac ischemia is 
common, and has been shown in large studies that post-
surgical troponin elevation increases the risk of short and 
long-term mortality and MACE [15–19]. A new term—
myocardial injury after noncardiac surgery (MINS) has 
been introduced in perioperative medicine [20], which 
carries a broader spectrum of myocardial injury than that 
defined by the universal myocardial infarction definition 
[21], and is frequent in vascular surgery [22].
Although MINS occurs after surgical revascularization 
for CLI and impacts outcomes, a little is known about the 
incidence and prognosis of myocardial injury following 
endovascular revascularization for CLI. Similar to sur-
gery, endovascular revascularization may provoke myo-
cardial ischemia, possibly by procedure-associated pain, 
catecholamine release, anemia, coagulation abnormalities, 
hypotension, tachycardia, and hypoxia [23, 24].
We conducted an observational cohort study in patients 
who underwent percutaneous endovascular revascularization 
for CLI conducted under local anesthesia to determine the 
incidence of myocardial injury and the relationship between 
myocardial injury and mortality and MACE at 1 year.
Methods
Study population
Between the years 2013 and 2015, we conducted a single-
center, prospective, observational cohort study of CLI 
patients undergoing endovascular revascularization in the 
Vascular Diseases Department of the Jagiellonian University 
Hospital, Krakow, Poland. Eligible patients were ≥ 45 years 
of age and stayed at least overnight in hospital after the end-
ovascular revascularization procedure. All patients fulfilled 
the definition of CLI according to current guidelines and 
were graded between 4 and 6 in the Rutherford classifica-
tion [6, 10]. Patients were excluded from the study if they 
declined consent or if the baseline high-sensitivie troponin T 
(hsTnT) measurement or at least one post-procedural hsTnT 
measurement was not available.
The Jagiellonian University ethics committee approved 
the study. The protocol complied with the Helsinki Declara-
tion, and all participants provided written informed consent 
before enrollment.
Study procedures
Initial assessment
Research personnel interviewed patients and reviewed their 
medical records to obtain information on patients’ medi-
cal history. Before the endovascular revascularization all 
patients had an ECG performed and blood samples were 
taken at admission for C-reactive protein (CRP) and cardiac 
biomarkers [i.e., N-terminal brain-type natriuretic peptide 
[NT-proBNP] and hsTnT (both Elecsys 2010 analyzer; 
Roche)]. Additional hsTnT measurements were performed 
3–6 h after endovascular revascularization and the fol-
lowing morning. The 99% threshold for hsTnT in healthy 
population is 14 ng/L (coefficient of variations < 10%) [25]. 
Preoperative estimated glomerular filtration rate (eGFR) 
was calculated using CKD-Epi equation and latest avail-
able preoperative serum creatinine value. Patients with an 
hsTnT ≥ 14 ng/L after their procedure had an ECG per-
formed and the presence of any clinical ischemic symptoms 
were recorded (e.g., chest pain, dyspnea).
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Follow-up
Research personnel followed patients throughout their hospi-
talization, and follow-up visits occurred in outpatient clinic 
at 1 month, 6 months and 1 year after endovascular revascu-
larization. If the patient died or suffered MACE, the research 
team obtained the source documentation. Patients who either 
refused or were not able to come for the follow-up visits 
were contacted by phone, or their next-of-kin were contacted 
if study personnel could not reach the patient.
Endovascular revascularization
Endovascular revascularization was performed under 
local anesthesia. Once vascular access was established, 
the obstructive lesions were crossed by means of various 
catheters and guidewires. Next, the lumen was dilated, and 
either isolated (in 74 patients, 31%) percutaneous translumi-
nal angioplasty (PTA) or PTA with subsequent bare metal 
stent implantation (in 165 patients, 69%) was performed. No 
drug-coated balloons were used in this study. All intravas-
cular instrumentations were performed under angiographic 
guidance. At the end of the procedure, the vascular sheath 
was removed and the puncture site was sealed by manual 
compression or using closure devices.
Study outcome measurements
We defined myocardial injury following endovascular treat-
ment as:
1) Post-procedural hsTnT ≥ 14 ng/L
with
2) ≥ 30% relative increase from the baseline hsTnT meas-
urement.
We also assessed other pre-specified myocardial injury 
thresholds: hsTnT ≥ 30; ≥ 40; ≥ 60; and ≥ 80 ng/L with the 
same obligatory relative increase of at least 30% from the 
baseline hsTnT level.
As there were no existing definitions of post-procedural 
myocardial injury at the time of the study commencement, 
the chosen obligatory relative increase of 30% in the hsTnT 
was based on previous studies that evaluated the delta 
changes in high-sensitive troponins levels, and suggested 
improved specificity for myocardial ischemia for this par-
ticular threshold [26].
The primary outcome was 1-year mortality, defined as 
death from any cause. The secondary outcome was major 
adverse cardiovascular event (MACE) that was defined as 
a composite of myocardial infarction, stroke and death (by 
any cause). If two events occurred in one patient (e.g., myo-
cardial infarction followed by death) the patient was counted 
as having a single MACE. All potential MACE events were 
adjudicated independently by two physicians (internist and 
cardiologist).
Statistical analyses
Categorical variables are presented as counts (percent-
ages), whereas continuous variables are reported as medians 
(25–75 quartile range) unless otherwise specified.
Categorical variables were compared between the groups 
who did and did not have myocardial injury by the chi-
square or the Fisher’s exact tests, and continuous variables 
were compared using the Student’s t test or the Mann–Whit-
ney U test as appropriate.
We undertook multivariable regression analyses and 
assessed the relationship between different thresholds of 
myocardial injury that occurred after revascularization 
with the outcomes, specifically the Cox proportional haz-
ard regression for evaluation of the mortality and logistic 
regression analysis for MACE. The independent variables 
included in the models by forced simultaneous entry were 
sex, Rutherford grade, CAD, history of MI, diabetes mel-
litus, and preoperative levels of eGFR, NT-proBNP, and 
hsTnT.
We reported results as hazard ratios (HR); for Cox analy-
ses and odds ratios (OR) for logistic regression, with the 
corresponding 95% confidence intervals and associated p 
values. As a measurement of discrimination, we assessed the 
C-index for Cox analyses and area under the curve (AUC) 
for logistic regression analyses. For all tests, we used a two-
sided alpha < 0.05 level of significance. All statistical analy-
ses were performed using R software, version 3.3.2 (Vienna, 
Austria).
Results
Patients and preoperative cardiac biomarkers
Two hundred and thirty-nine consecutive patients were 
included; all patients were Caucasian, 56% were male, and 
the mean age was 71.5 ± 10.1 years. Almost 80% of patients 
had a Rutherford grade ≥ 5 before their procedure, and most 
had multiple risk factors for cardiovascular diseases (e.g., 
48% had known coronary artery disease and 20% conges-
tive heart failure). Only one patient was lost to follow-
up at 1-year. Figure 1 presents the study flow chart, and 
Table 1 reports the clinical and laboratory characteristics 
of included patients. During the 1-year follow-up period, 
MACE occurred in 48 patients (20.5%) and 34 patients died 
(14.2%). Outcomes up to 1-year are presented in Table 2.
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In 232 patients (97.1%), hsTnT in all three points of 
measurement were available for the analysis (seven patients 
did not have hsTnT measured on the morning following 
endovascular revascularization). Median baseline hsTnT 
level was 18 (12–29) ng/L and 151 patients (62.1%) had an 
hsTnT above the threshold level of 14 ng/L. Median baseline 
NT-proBNP was 558 (195–1565) pg/mL (Table 2), and in 
78 patients (32%) the level of NT-proBNP was above the 
age-adjusted reference value [27].
Myocardial injury after endovascular 
revascularization
Median hsTnT was 18 (12–31.5) after 3–6 h from treat-
ment and 21 (13–41) on the following morning. Myocardial 
injury based on the hsTnT threshold ≥ 14 ng/L and relative 
troponin increase of at least 30% occurred in 61 patients 
(25.5%). Patients with myocardial injury (≥ 14 ng/L) when 
compared to those without myocardial injury, were older, 
more frequently had congestive heart failure, beta-blocker 
usage, and higher baseline levels of white blood cells, CRP, 
baseline hsTnT and NT-proBNP and lower baseline levels 
of eGFR and hemoglobin. The comparison of patients’ char-
acteristics, treatments and laboratory findings between those 
that suffered myocardial injury (≥ 14 ng/L) and that did not 
is presented in Table 1.
In the myocardial injury (≥ 14 ng/L) group, the peak 
(maximum) hsTnT was found in 16.3% of patients 6–12 h 
after the revascularization, and in the majority (83.7%) 
by the next morning. Only six patients (9.8%) with 
Fig. 1  Study flow chart
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myocardial injury (≥ 14 ng/L) had ischemic symptoms 
(e.g., chest discomfort was present in three) and presumed 
new ECG ischemic changes. Three additional patients had 
new ECG ischemic finding without clinical symptoms. In 
total, nine patients (14.8%) in the myocardial injury group 
presented with any ischemic symptoms (clinical symptoms 
and/or ECG changes).
Myocardial injury and 1‑year outcomes
Patients who developed myocardial injury were more likely 
to die or suffer MACE within the 1-year follow-up after 
revascularization compared to the patients who did not have 
myocardial injury. 17/34 (50%) of patients that died in the 
first year had myocardial injury (≥ 14 ng/L). The outcomes 
Table 1  Baseline characteristics
Continuous variables expressed as medians with 25–75 quartile range unless otherwise specified
ACE angiotensin converting enzyme, ASA acetylsalicylic acid, BMI body mass index, CAD coronary artery disease, CRP C-reactive protein, 
GFR glomerular filtration rate, HgB hemoglobin, hsTnT high-sensitive troponin T, NT-proBNP N-terminal brain natriuretic peptide, SD standard 
deviation, TIA transient ischemic attack, WBC white blood cells
All patients (n = 239) Patients without myocardial 
injury (n = 178)
Patients with myocardial 
injury (n = 61)
p value
Age (years) (mean ± SD) 71.5 ± 10.1 70.5 ± 10.2 74.4 ± 9.4 0.007
Age > 75 years n (%) 97 (40.6%) 62 (34.8%) 35 (57.3%) 0.003
Male n (%) 134 (56.1%) 106 (59.6%) 28 (45.9%) 0.07
BMI kg/m2 (mean ± SD) 26.8 ± 4.7 26.8 ± 4.6 27.1 ± 5.3 0.809
Past medical history
 Hypertension n (%) 183 (76.6%) 133 (74.7%) 50 (82%) 0.295
 Diabetes mellitus n (%) 138 (57.7%) 100 (56.2%) 38 (62.3%) 0.454
 Insulin treatment 108 (45.2%) 78 (43.8%) 30 (49.2%) 0.551
 CAD n (%) 115 (48.1%) 81 (45.5%) 34 (55.7) 0.184
 Myocardial infarction n (%) 59 (24.7%) 41 (23.0%) 18 (29.5%) 0.308
 TIA/stroke n (%) 44 (18.4%) 32 (18.0%) 12 (20%) 0.848
 Chronic heart failure n (%) 48 (20.1%) 28 (15.7%) 20 (32.8%) 0.006
 Dialysis n (%) 12 (5.0%) 8 (4.5%) 4 (6.6%) 0.508
 Prior smoker n (%) 170 (71.1%) 126 (70.8%) 44 (72.1%) 0.872
 Current smoker n (%) 30 (12.6%) 25 (14.0%) 5 (8.2%) 0.271
 Rutherford 4 n (%) 49 (20.5%) 40 (22.5%) 9 (14.8%) 0.2698
 Rutherford 5 n (%) 150 (62.8%) 112 (62.9%) 38 (62.3%) 1
 Rutherford 6 n (%) 40 (16.7%) 26 (14.6%) 14 (23%) 0.163
Treatment
 ASA 234 (97.9%) 174 (97.8%) 60 (98.4%) 1
 Clopidogrel 227 (95.0%) 171 (96.1%) 56 (91.8%) 0.1895
 Statin 208 (87.0%) 160 (89.9%) 48 (78.7%) 0.044
 B-blocker 141 (59.0%) 95 (53.4%) 46 (75.4%) 0.003
 ACE inhibitor 144 (60.3%) 104 (58.4%) 40 (65.6%) 0.365
 Heparin 165 (69.0%) 118 (66.3%) 47 (77%) 0.149
 Oral diabetes drugs 55 (23.0%) 42 (23.6%) 13 (21.3%) 0.86
Laboratory parameters
 Hb g/dL 12.4 (10.9–13.5) 12.6 (11.3–13.6) 11.4 (10.6–12.4) 0.001
 WBC count × 103 cells/μ/L 8.2 (6.9–10.8) 8.0 (6.74–10.8) 8.7 (7.5–10.9) 0.04
 Platelet count × 103 cells/μ/L 233.5 (190–311) 230 (190–307) 255 (194–319) 0.622
 CRP mg/L 7.4 (2.1–41.2) 6.1 (1.8–28.8) 15.5 (2.8–61.2) 0.019
 CRP > 5 mg/L n (%) 144 (60.3%) 100 (56.2%) 44 (72.1%) 0.034
 Creatinine μmol/L 83 (67–102) 81 (65.5–99) 87 (68.8–110) 0.22
 eGFR 74 (56–96) 78 (57.3–98.8) 65.5 (50.3–87.8) 0.031
 Preoperative hsTnT ng/L 18 (12–29) 17 (11–27) 22 (14–35.5) 0.017
 NT-proBNP pg/ml median (Q1–Q3) 558 (195–1565) 459 (159–1365) 1061 (471–2490) < 0.001
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in unadjusted analysis for both 1-year mortality and MACE 
for different hsTnT thresholds for myocardial injury are pre-
sented in Table 3.
In the multivariable analysis, myocardial injury was 
found to be an independent predictor of both 1-year mortal-
ity and MACE. Adjusted hazard ratio for the association of 
myocardial injury after EVT with 1-year mortality varied 
from aHR: 2.44 (95% CI 1.18–5.01) for hsTnT ≥ 14 ng/L to 
aHR: 3.34 (95% CI 1.29–8.65) for myocardial injury after 
EVT ≥ 80 ng/L. Similar results were found for 1-year MACE 
with adjusted OR ranging from OR 2.89 (95% CI 1.41–5.92) 
to OR 6.69 (95% CI 2.17–20.68). Table 4 reports the 1-year 
mortality and MACE multivariable risk prediction models 
that included myocardial injury (≥ 14 ng/L). Table 5 reports 
the comparison of different myocardial injury thresholds on 
the risk of 1-year mortality and MACE.
In sensitive analysis with exclusion of sympto-
matic patients that developed myocardial injury for the 
hsTnT ≥ 14 ng/L threshold (i.e., suffered MI), both the 
1-year mortality (aHR: 2.19; CI 1.02–4.68; p = 0.04), and 
1-year MACE (OR 2.25; CI 1.06–4.77; p = 0.036) remained 
significant.
Discussion
Given the burden of cardiovascular complications follow-
ing revascularization for CLI, there is a need to understand 
potential precipitants of these adverse outcomes. We evalu-
ated the influence of myocardial injury after endovascular 
treatment in CLI patients on 1-year mortality and MACE. 
The findings show that (1) preoperative cardiac biomark-
ers (hsTnT and NT-proBNP) are frequently elevated in CLI 
patients, (2) almost 25% of CLI patients experience myocar-
dial injury after endovascular treatment, and (3) myocardial 
injury is independently associated with 1-year mortality and 
MACE.
Table 2  Outcomes in studied group
Continuous variables expressed as medians with 25–75 quartile range unless otherwise specified
MI myocardial infarction
All patients (n = 239) Patients without myocardial 
injury (n = 178)
Patients with myocardial 
injury (n = 61)
p value
Death (up to 1 year) n% 34 (14.2%) 19 (10.7%) 15 (24.6%) 0.011
MI (up to 1 year) n% 16 (6.7%) 7 (3.9%) 9 (14.8%) 0.007
Stroke (up to 1 year) n% 9 (3.8%) 6 (3.3%) 3 (4.9%) 0.697
Composite end point (up to 1 year) n% 48 (20.1%) 27 (15.2%) 21 (34.4%) 0.003
Amputation below knee (up to 1 year) n% 8 (3.3%) 6 (3.4%) 2 (3.2%) 1
Amputation above knee (up to 1 year) n% 23 (9.6%) 18 (10.1%) 5 (8.2%) 0.804
Re-intervention (up to 1 year) n% 106 (44.3%) 83 (46.6%) 23 (37.7%) 0.237
Table 3  Univariate comparison of patients that suffered myocardial injury (with different hsTnT thresholds) and those that did not in terms of 
1-year outcomes
*Myocardial injury for different post-procedural hsTnT thresholds with obligatory relative increase ≥ 30% from the baseline hsTnT measurement
CI confidence interval, MACE major adverse cardiovascular events, OR odds ratio
Myocardial injury 
TnT threshold 
(ng/L)
Presence of 
myocardial 
injury*
ALL n = 239 Death at 1-year OR (95%CI) unad-
justed
p value MACE OR (95%CI) unad-
justed
p value
14 No 178 (74.5%) 19 (10.7%) Reference 27 (15.1%) Reference
Yes 61 (25.5%) 15 (24.6%) 2.73 (1.3–5.8) 0.011 21 (34.4%) 2.94 (1.50–5.73) 0.003
30 No 197 (82.4%) 23 (11.7%) Reference 33 (16.8%) Reference
Yes 42 (17.6%) 11 (26.2%) 2.68 (1.19–6.06) 0.026 15 (35.7%) 2.76 (1.33–5.75) 0.01
40 No 204 (85.4%) 23 (11.3%) Reference 34 (16.7%) Reference
Yes 35 (14.6%) 11 (31.43%) 3.61 (1.56–8.32) 0.004 14 (40%) 3.33 (1.54–7.20) 0.003
60 No 216 (90.4%) 25 (11.6%) Reference 37 (17.1%) Reference
Yes 23 (9.6%) 9 (39.1%) 4.91 (1.93–12.5) 0.0016 11 (47.8%) 4.43 (1.82–10.8) 0.002
80 No 222 (92.9%) 27 (12.2%) Reference 38 (17.1%) Reference
Yes 17 (7.1%) 7 (41.2%) 5.06 (1.78–14.4) 0.004 10 (58.8%) 6.92 (2.48–19.3) < 0.001
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CAD is known to be present in 50–60% of patients with 
CLI [11, 28] and is included in all of the risk stratification 
tools as a predictor of mortality. In a recent study by Chen 
and colleagues, the presence of CAD in CLI patients under-
going diagnostic angiography or endovascular treatment was 
associated with higher rate of 5-year mortality and major 
cardiovascular complications [29].
However, the presence of CAD may be underestimated 
in patients with CLI, who often suffer from diabetes and 
immobilization and do not present with typical (angina) 
chest pain. A large trial that evaluated coronary angio-
grams before vascular surgery in almost 300 patients with 
CLI found that only 8% had coronary arteries without ath-
erosclerosis [30].
The recent introduction of the hsTnT assay enables the 
detection of limited myocardial injury even without tis-
sue necrosis, and together with BNP evaluation may help 
in diagnosing cardiac diseases. Both troponins and BNP 
have been broadly studied in several medical conditions 
and their elevation have been associated with the presence 
Table 4  Multivariable risk prediction model of 1-year mortality and MACE in CLI patients including myocardial injury after endovascular 
revascularization (≥ 14 ng/L and ≥ 30% relative increase in hsTnT) and baseline cardiac biomarkers (hsTnT and NT-pro-BNP)
CRP, eGFR, TnT and NT-proBNP expressed in the model as continuous variables. Cox proportional hazard analysis for the 1-year mortality 
model [C-index = 0.677 (SE = 0.051)] with the corresponding adjusted hazard radio (aHR) and 95% confidence interval (CI); multivariable logis-
tic regression for 1-year MACE model [AUC = 0.65] with the corresponding adjusted odds ratio and 95% CI
CAD coronary artery disease, CI confidence interval, CRP C-reactive protein, DM diabetes mellitus, eGFR estimated glomerular filtration rate, 
MACE major adverse cardiovascular events, MI myocardial infarction, NT-pro-BNP N-terminal brain natriuretic peptide, TnT troponin T
1-year mortality 1-year MACE
Adjusted hazard ratio (95% CI) p value Adjusted OR (95% CI) p value
Age 0.99 (0.95–1.033) 0.653 0.99 (0.96–1.03) 0.715
Sex
 Female Reference Reference
 Male 0.71 (0.31–1.64) 0.426 0.84 (0.39–1.82) 0.658
Rutherford
 4 Reference Reference
 5 1.52 (0.50–4.59) 0.461 1.259 (0.49–3.26) 0.634
 6 1.037 (0.26–4.17) 0.959 0.888 (0.25–3.10) 0.853
CAD 1.64 (0.66–4.09) 0.288 1.37 (0.56–3.35) 0.492
History of MI 0.87 (0.33–2.269) 0.768 1.19 (0.47–3.04) 0.714
DM 0.89 (0.41–1.93) 0.773 1.19 (0.57–2.48) 0.639
CRP 1.005 (0.999–1.011) 0.087 1.004 (0.997–1.01) 0.296
eGFR 1.002 (0.991–1.014) 0.719 0.9997 (0.9882–1.011) 0.956
NT-proBNP 1.00004 (0.999–1.00009) 0.149 1.00005 (0.99998–1.00012) 0.152
TnT0 1.002 (0.994–1.01) 0.649 0.999 (0.987–1.011) 0.868
Myocardial injury: hsTnT ≥ 14 ng/L with 
≥ 30% relative hsTnT increase
2.44 (1.18–5.06) 0.016 2.89 (1.41–5.92) 0.004
Table 5  Summary of 
multivariable results for 
different hsTnT myocardial 
injury thresholds and risk 
prediction of 1-year mortality 
and MACE
*Myocardial injury for different post-procedural hsTnT thresholds with obligatory relative increase ≥ 30% 
from the baseline hsTnT measurement
AUC area under the curve, CI confidence interval, MACE major adverse cardiovascular events, OR odds 
ratio
Myocardial injury 
TnT threshold* 
(ng/L)
1-year mortality 1-year MACE
Adjusted hazard 
ratio (95% CI)
p value C-index Adjusted OR (95% CI) p value AUC
≥ 14 2.44 (1.18–5.06) 0.016 0.7 2.89 (1.41–5.92) 0.004 0.697
≥ 30 2.37 (1.09–5.17) 0.03 0.694 2.67 (1.20–5.90) 0.016 0.683
≥ 40 2.97 (1.35–6.55) 0.007 0.705 3.09 (1.33–7.14) 0.008 0.684
≥ 60 3.49 (1.49–8.14) 0.004 0.698 3.98 (1.50–10.56) 0.005 0.689
≥ 80 3.34 (1.29–8.65) 0.013 0.694 6.692 (2.17–20.68) 0.001 0.7
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of coronary artery disease, congestive heart failure and 
overall poor prognosis [31–34].
Pohlhammer and colleagues demonstrated that hsTnT is 
elevated in males with PAD when compared to diabetes-
matched controls, and that hsTnT elevation correlated with 
the presence of cardiovascular diseases [35]. In another 
study in CLI patients, elevated TnI was associated with 
increased mortality over a median of 8 months (HR 3.1; 
95% CI 1.6–5.6) [36]. Both hsTnT [37] and BNP [38] 
among PAD patients were reported to be the highest in 
CLI patients.
In our study, we found that 62.1% of patients had pre-
procedural hsTnT values above the 99% percentile of 
a normal reference level and 32% of patients had age-
adjusted elevated NT-proBNP. According to past medi-
cal histories, the majority of patients had several car-
diovascular comorbidities (e.g., hypertension, diabetes), 
with known coronary artery disease being present in 48% 
and known congestive heart failure in 20%. Considering 
the results of studied biomarkers cardiac disease may be 
underestimated in CLI patients.
Further, preoperative elevated cardiac biomarkers in CLI 
patients may reflect cardiac comorbidities (e.g., coronary 
artery disease, congestive heart failure and other cardiac 
conditions present in the clinical model), yet they may not 
be independently associated with post-procedural outcome 
(Table 4). Indeed, our data suggests that the only determi-
nant of subsequent prognosis is dependent on monitoring 
the perioperative troponin response indicating myocardial 
injury.
The current study demonstrated a high prevalence of 
myocardial injury following revascularization. In the low-
est evaluated threshold (hsTnT ≥ 14 ng/L; with at least 30% 
relative increase from the baseline level), myocardial injury 
was found in 25.5% of patients. Only a minority of patients 
(14.8%), who suffered myocardial injury after endovas-
cular revascularization experienced clinical symptoms or 
had ECG findings indicative of myocardial ischemia. This 
would suggest that routine troponin monitoring is neces-
sary in these patients, as opposed to symptom initiated tro-
ponin surveillance which would result in missing most of 
the patients who sustain myocardial injury. Despite being 
clinically silent, myocardial injury proved to be an independ-
ent predictor of both 1-year mortality and MACE. The inci-
dence of 1-year mortality in the myocardial injury group was 
at least 25% in the lowest threshold and surpassed 40% in 
the highest. Similar findings were shown for 1-year MACE 
outcomes. These findings may partly explain why despite all 
the technical improvements in revascularization techniques, 
the mortality rate after revascularization has remained at 
a high level for the past several decades, [39] as we have 
not been able to adequately identify patients at risk without 
postoperative troponin surveillance.
To our knowledge, this is the first study evaluating myo-
cardial injury after endovascular treatment in CLI patients 
with almost 100% complete follow-up.
Our study has limitations. Statistical association of myo-
cardial injury with final outcomes was based on a priori 
specified thresholds. It is possible that our thresholds are 
not optimal, and should be re-evaluated in other studies. 
Troponins were measured after the treatment only at two 
time points with the possibility that we missed elevated 
troponins on the following days after EVT. Our approach 
to troponin surveillance was, however, pragmatic, as most 
of the patients are discharged on the day after endovascu-
lar revascularization, and further measurements would not 
be available. Finally, troponin elevation after endovascular 
revascularization might have resulted from etiologies other 
than ischemia. Further studies evaluating the mechanism of 
myocardial injury after endovascular revascularization are 
needed.
Conclusions
Preoperative troponins and NT-proBNP are commonly ele-
vated in patients with CLI undergoing endovascular proce-
dures suggesting high risk of cardiac diseases. One in four 
revascularization patients experienced myocardial injury 
after endovascular revascularization with > 25% mortality 
within the subsequent year suggesting that myocardial injury 
is a trigger for future outcomes. The majority of patients 
who experienced myocardial injury after revascularization 
did not present with clinical signs or ECG changes indicative 
of myocardial ischemia, and would probably go unnoticed 
without troponin screening.
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